New Delhi, 30 May (IANS). Taking a historic step towards strengthening consumer protection and regulatory monitoring in the field of traditional medicine, the Union Ministry of AYUSH launched the ‘AYUSH Safety Portal’ on Friday. This will serve as a cautious monitoring against misinformation.
Union AYUSH Minister Prataprao Jadhav launched this portal at Ayush Bhawan in New Delhi. It is important to address misleading advertisements and adverse drug response issues.
Jadhav said, “With the launch of AYUSH Safety Portal, we are empowering citizens and professionals to become active partners in protecting the integrity of AYUSH system. This platform will act as a vigilant monitoring against misleading advertisements and will ensure that only safe and reliable products reach people.”
The AYUSH safety portal represents a significant progress in bringing pharmacovizlance and regulators on a platform within the Ayush Ecosystem.
This will assist with a centralized and accessible dashboard of cases reported to the Ministry of AYUSH, which will lead to real -time tracking, quick regulatory action and detailed data analysis.
This portal allows consumers, health professionals, and regulatory officers to report and monitor misleading advertisements and adverse drug responses through a spontaneous digital process, developed with technical collaboration with the Central Siddha Research Council (CCRS) and align with the National Pharmacovizlance Program.
Vaidya Rajesh Kotecha, Secretary, Ministry of AYUSH said, “By integrating the data of state licensing authorities, national pharmacovizlane centers and major regulatory stakeholders, portal provides real -time monitoring, systematic analysis and coordinated action on misleading advertisements and adverse drug reactions. We have made it accessible to the public so that we have made it accessible to the public so that any citizen can report to the public directly.
The Ayush Suraksha Portal has been developed as per the Supreme Court’s order of 30 July 2024 in the writ petition (Civil) No. 645/2022. In this, the court emphasized the requirement of a centralized dashboard for monitoring advertisements and adverse drug response related data monitoring and publication.
-IANS
SCH/Ekde
